SARS-CoV-2 might directly activate NLRP3 inflammasome resulting in an endogenous adjuvant activity necessary to mount a proper adaptive immune response against the virus. Heterogeneous response of COVID-19 patients could be attributed to differences in not being able to properly downregulate NLRP3 inflammasome activation. This relates to the fitness of the immune system of the individual challenged by the virus. Patients with a reduced immune fitness can demonstrate a dysregulated NLRP3 inflammasome activity resulting in severe COVID-19 with tissue damage and a cytokine storm. We sketch the outlines of five possible scenarios for COVID-19 in medical practice and provide potential treatment options targeting dysregulated endogenous adjuvant activity in severe COVID-19 patients.
【저자키워드】 COVID-19, therapy, HMGB1, NLRP3 inflammasome, endogenous adjuvant activity, 【초록키워드】 SARS-CoV-2, Cytokine storm, severe COVID-19, immune system, virus, immune, Adaptive immune response, COVID-19 patient, Activation, tissue damage, potential treatment option, severe COVID-19 patients, FIVE, resulting, reduced, activate, dysregulated, downregulate, 【제목키워드】 NLRP3,